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Introduction
Insulin-like peptide 5 (INSL5) was first identified through a
search of the expressed sequence tags (EST) databases for
novel insulin-like sequences.
[1] Primary structure analysis
showed it to comprise of 135 amino acid residues with a
signal peptide, B, that connected the C and A domains. It is
postulated to be processed in vivo to yield a two-chain struc-
ture (A and B) that contains the insulin-like disulfide cross-
links; this makes it a bona fide member of the insulin super-
family. The predicted primary structure of INSL5 consists of a
twenty one residue A chain and a twenty four residue B chain
that are linked by three disulfide bonds (Figure 1). Other mem-









[9] and relaxin-3 (H3 relaxin/
INSL7).
[10] Northern blot analysis showed highest expression of
human INSL5 in rectal and colon tissue;
[1] this suggests a prob-
able role in gut contractility. Quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) revealed the presence of
INSL5 mRNA in a variety of human tissues, including the pitui-
tary and, in lower levels, in the brain.
[11]
In the mouse, the highest expression of INSL5 mRNA is in
the colon
[1] and kidney.
[12] An INSL5 knockout mouse has been
developed, which includes a lacZ reporter gene to track INSL5
expression at the cellular level.
[13] Although the phenotype of
this mouse was not reported, lacZ expression was seen in a
discrete population of cells in the colon. Although Northern
blot analysis showed that INSL5 mRNA was absent in brain
tissue or the pituitary,
[1] RT-PCR showed the presence of INSL5
mRNA in the hypothalamus.
[14] Immunohistochemical studies
with an antiserum against the mouse INSL5 peptide showed
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Insulin-like peptide 5 (INSL5) was first identified through searches
of the expressed sequence tags (EST) databases. Primary se-
quence analysis showed it to be a prepropeptide that was pre-
dicted to be processed in vivo to yield a two-chain sequence (A
and B) that contained the insulin-like disulfide cross-links. The
high affinity interaction between INSL5 and the receptor RXFP4
(GPCR142) coupled with their apparent coevolution and partially
overlapping tissue expression patterns strongly suggest that
INSL5 is an endogenous ligand for RXFP4. Given that the primary
function of the INSL5–RXFP4 pair remains unknown, an effective
means of producing sufficient quantities of this peptide and its
analogues is needed to systematically investigate its structural
and biological properties. A combination of solid-phase peptide
synthesis methods together with regioselective disulfide bond for-
mation were used to obtain INSL5. Both chains were unusually
resistant to standard synthesis protocols and required highly opti-
mized conditions for their acquisition. In particular, the use of a
strong tertiary amidine, DBU, as N
a-deprotection base was re-
quired for the successful assembly of the B chain; this highlights
the need to consider incomplete deprotection rather than acyla-
tion as a cause of failed synthesis. Following sequential disulfide
bond formation and chain combination, the resulting synthetic
INSL5, which was obtained in good overall yield, was shown to
possess a similar secondary structure to human relaxin-3 (H3 re-
laxin). The peptide was able to inhibit cAMP activity in SK-N-MC
cells that expressed the human RXFP4 receptor with a similar ac-
tivity to H3 relaxin. In contrast, it had no activity on the human
RXFP3 receptor. Synthetic INSL5 demonstrates equivalent activity
to the recombinant-derived peptide, and will be an important
tool for the determination of its biological function.
Figure 1. Predicted primary structure of INSL5.
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paraventricular, supraoptic, accessory secretory, and supraoptic
retrochiasmatic nuclei, and immunoreactive cell processes in
the internal layer of the median eminence.
[14] This is the first
evidence that this peptide is expressed in a population of cells
in the mouse hypothalamus and pituitary, and that it elevates
internal [Ca
2+] by a mechanism that involves both Ca
2+ influx
and Ca
2+ release from intracellular stores. The high concentra-
tion of irINSL5 in the hypothalamic-pituitary axis suggests a
neuroendocrine function of this insulin superfamily member in
the mouse.
INSL5 shows the highest sequence similarity to H3 relaxin,
[15]
and was predicted to bind to relaxin family peptide (RXFP) re-
ceptors. Additionally, both the INSL5 and RXFP4 genes are dys-
functional in the rat and dog genomes; this suggested that
INSL5 is the native ligand of RXFP4.
[11] It was subsequently
shown that, in vitro, INSL5 binds to RXFP4 with an affinity
equal to that of H3 relaxin.
[11] Importantly, INSL5 does not acti-
vate RXFP3, however, it does bind to the receptor with low af-
finity and can act as a weak antagonist. INSL5 neither shows
binding affinity for nor activity on either RXFP1 or RXFP2.
These results together with their coevolution and partially
overlapping tissue expression patterns strongly suggest that
INSL5 is an endogenous ligand for RXFP4.
[11]
While the primary functions of the INSL5–RXFP4 pair remains
unknown, its expression profile, unlike other relaxin family
members (e.g., H2 relaxin, INSL3, etc.), suggests a nonrepro-
ductive role. In order to systematically investigate its structural
and in vitro biological properties, an effective means of pro-
ducing sufficient quantities of this peptide and its analogues is
needed. We present here a significant contribution to INSL5 re-
search, namely the first optimized chemical synthesis protocol
for its preparation. We also report here the solution conforma-
tion of the peptide and confirm an insulin-like fold. Finally, we
characterize its activity on the INSL5 receptor, RXFP4.
Results and Discussion
Synthesis of INSL5 A chain
The INSL5A chain was found to be unusually difficult to syn-
thesize with standard Fmoc-continuous flow methodology
with piperidine (20%)/DMF solution for N
a-Fmocremoval and
HBTU as a coupling agent. A potential source of the difficulty
is the presence of multiple Asp residues. The most frequently
encountered side reaction that affects Asp residues during
solid phase peptide synthesis (SPPS) is aspartimide formation;
this results from a ring closure between the nitrogen of the a-
carboxyl amide bond and the b-carboxyl side chain, with the
loss of the ester protecting group.
[16] It is a particularly serious
problem in Fmoc-SPPS when cyclization is driven by base used
to effect Fmoc-group removal.
[17,18] The INSL5 A chain was pre-
dicted to be more susceptible to aspartimide formation be-
cause of the presence of the Asp–Gly sequence in the middle
of the chain. It has been previously reported that the Asp–Gly
sequence causes as much as 0.5% aspartimide formation per
N
a-Fmoc deprotection cycle.
[19] It can be exacerbated by the
use of 1,8-diazabicycloACHTUNGTRENNUNG[5.4.0]undec-7-ene (DBU), which has
been shown to more effectively promote aspartimide forma-
tion than piperidine. Of the various approaches that have been
advocated to overcome this problem, such as the addition of
dinitrophenol or HOBt to the piperidine solution, only the
masking of the Asp–Gly amide bond with 2-hydroxy-4-
methoxyACHTUNGTRENNUNGbenzyl (Hmb) offers complete protection.
[19,20] Howev-
er, the acylation of the Hmb derivatives can be problematic,
and the reaction is difficult to follow and often requires non-
standard acylation conditions. One solution is to use the com-
mercially available dipeptide, Fmoc-AspACHTUNGTRENNUNG(OtBu)-(Hmb)Gly-OH.
[21]
This derivative is introduced by using standard coupling meth-
ods and extends the peptide chain by two residues in one
step. Its use has also the additional advantage of overcoming
aggregation during chain extension. However, use of this di-
peptide is not a cost-effective way to generate peptides. The
coupling of the amino acid following this dipeptide is also
problematic because of the presence of bulky Hmb side chain
in the dipeptide. However, the much cheaper Gly derivative,
Fmoc-(Dmb)Gly-OH, which is now commercially available, can
also effectively prevent aspartimide formation and chain ag-
gregation.
[22] Use of Fmoc-(Dmb)Gly-OH in the middle of the
chain together with one pseudoproline, Fmoc-Leu-Ser-
ACHTUNGTRENNUNG(y
MeMePro)-OH, at the C-terminal region resulted in a crude A-
chain peptide with an excellent HPLC profile (Figure 2).
Synthesis of INSL5 B chain
The B chain of INSL5 was also very difficult to synthesize. The
use of standard Fmoc-continuous flow methodology with pi-
peridine (20%)/DMF and HBTU gave a crude product that was
shown by both RP-HPLC and MALDI-TOF MS to possess multi-
ple deletion peptides (Figure 3A). As the peptide does not
contain an Asp residue, aspartimide formation is not a contrib-
utor to the poor quality. During Fmoc-SPPS, aggregation
through interchain association of the growing resin-bound
peptides is known to contribute to the difficulty of the synthe-
sis.
[23,24] Aggregation typically results in a decrease in the rates
of acylation and deprotection and consequently leads to the
Figure 2. RP-HPLC profile of: A) crude reduced [Cys7,12 (SH), Cys8 (But),
Cys21 (Acm)], and B) purified oxidized human [Cys8 (But), Cys21 (Acm)]
INSL5 A chain; eluant A: 0.1% aq. TFA; eluant B: 0.1% TFA in acetonitrile;
gradient=20–50% B over 30 min; Phenomenex C18 column, pore size
300  , particle size 5 mm, 4.6 250 mm.
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Synthetic Human Insulin-Like Peptide 5production of deletion products of various length and compo-
sition. Such a decrease in the purity of the crude material
often results in subsequent difficult purification. Strategies to
combat Fmoc-SPPS resin-bound aggregation and improve syn-
thetic product yield include the use of more potent acylation
reagents,
[25] backbone amide protection,
[26,27] incorporation of
pseudoproline,
[28,29] microwave irradiation to enhance coupling
efficiency,
[30] SPPS at elevated temperatures,
[30] and use of DBU
instead of piperidine to deprotect the N-terminal Fmoc
group.
[31] A repeat assembly of the INSL5 B chain was under-
taken by using microwave-assisted coupling and deprotection.
However, it did not afford any improvement in crude peptide
purity (Figure 3B). A third assembly of the chain was then un-
dertaken by using a psuedoproline, Fmoc-SerACHTUNGTRENNUNG(tBu)-Ser-
ACHTUNGTRENNUNG(y
MeMePro)-OH, at the C terminus without success (Figure 3C).
A fourth assembly of the peptide was undertaken by using
HATU as coupling reagent instead of HBTU and an increase in
amino acid acylation time from 30 min to 1 h. Again, no signifi-
cant improvement in the synthetic product was observed by
RP-HPLC (Figure 3D). Finally, use of default conditions (de-
scribed in the legend of Figure 3A) together with simple re-
placement of piperidine with the stronger base, DBU (2%)/
DMF, which has previously been shown in our laboratory to be
effective for Fmoc deprotection in “difficult sequences”,
[31] and
no other synthesis protocol change resulted in very good qual-
ity crude product, which was shown by MALDI-TOF MS to
comprise the correct molecular mass (Figure 3E). This showed
that incomplete N
a-Fmocgroup removal was, in fac t, the
major problem in Fmoc-SPPS of the INSL5 B chain rather than
incomplete acylation. This is further highlighted by the fact
that this simple protocol did not use a pseudoproline residue
in the assembly.
Chain combination
Until recently, relaxin and other insulin-like peptides were com-
monly prepared in our laboratory by random combination of
the individual S-reduced A and B chains.
[32–34] Following their
chemical synthesis, the purified chains are combined in solu-
tion at high pH to produce the target peptide in modest to
good overall yield. Surprisingly, however, both INSL4 and
H3 relaxin have not been successfully prepared by the
random-combination method. For this reason, a “forced” tech-
nique, that is, regioselective disulfide bond formation was ap-
plied to successfully synthesize not only INSL4
[35] and H3 re-
laxin,
[36] but also equine
[37] and mouse relaxins.
[38] A variety of
insulins, relaxins, and their analogues have now been synthe-
sized successfully by using this approach.
[39–41] Therefore, to
avoid the uncertainty of the random-combination method, this
approach has been used here for the synthesis of INSL5. Differ-
ential cysteine S-protecting groups (specifically, Trt, But, and
Acm) were used to allow their sequential removal or modifica-
tion followed by directed formation of three disulfide bonds
(for details see the Experimental Section). Solid phase synthesis
of the separate, selectively S-protected A and B chains fol-
lowed by their purification and subsequent stepwise formation
of each of the three disulfides by oxidation, thiolysis, and io-
dolysis (Figure 4A) led to the successful acquisition of INSL5
(3.5% overall yield relative to starting B chain) in very high
purity as assessed by RP-HPLC (Figure 4B) and MALDI-TOF MS.
This yield compares well to that obtained for synthetic H3 re-
laxin (6%).
[36]
Figure 3. RP-HPLC profile of crude [Cys7 (SH), Cys19 (Acm)] INSL5 B chain
obtained under different SPPS conditions: A) synthetic peptide obtained by
using standard reaction conditions, that is, Fmoc-deprotection with piperi-
dine (20%), 30 min acylation with HBTU-activated amino acid; B) microwave-
assisted acylation and deprotection; C) after introduction of a psuedopro-
line, Fmoc-SerACHTUNGTRENNUNG(tBu)-SerACHTUNGTRENNUNG(y
MeMePro)-OH, into the sequence; D) use of HATU as
acylating reagent, reaction time 1 h; E) use of DBU for Fmoc removal;
(eluant A: 0.1% aq. TFA; eluant B: 0.1% TFA in acetonitrile; gradient=10–
90% B over 30 min; Phenomenex C18 column, pore size 300  , particle size
5 mm, 4.6 250 mm).
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Circular dichroism (CD) spectroscopy: The conformation of the
synthetic human INSL5 was analyzed by CD spectroscopy
(Figure 5). The CD for H3 relaxin was also measured for com-
parison because of its sequence similarity with INSL5. The stud-
ies revealed that both peptides possess a significant degree of
a-helical conformation along with b sheet and/random-coiled
structure. The a-helical content of INSL5, which was calculated
from the mean residual weight ellipticity at 222 nm, [q]222,
[42]
was found to be 38.28% ([q]222=13505.0), which is almost the
same as H3 relaxin ([q]222=13384.0, helix content=37%).
NMR spectroscopy: To gain further insight into the fold of
the peptide and to confirm its insulin-like structure we subject-
ed the peptide to high-field solution NMR spectroscopy. As is
evident from Figure 6, which shows the fingerprint region of a
NOESY spectrum, the spectral data were of high quality and
showed excellent signal dispersion; this is consistent with a
highly structured peptide. Partial resonance assignments were
achieved by using 2D sequential assignment strategies and the
assignments and secondary chemical shifts were consistent
with the insulin-like fold, as reported in the NMR spectroscopy
studies of the H3 relaxin and INSL3 peptides.
[43,44] The fold is
characterized by mainly helical regions, but a small extended
region with cross-strand interactions between the two peptide
chains is also present.
Activity on RXFP3 and RXFP4
The syntheticINSL5 peptide was tested for its ability to inhibit
forskolin induced cAMP activity in RXFP3 and RXFP4 transfect-
ed cells (Figure 7). As expected the peptide did not demon-
strate any activity on RXFP3, although H3 relaxin displayed
similar high activity to that previously reported
[36] (Table 1). In
contrast INSL5 was able to decrease forskolin induced cAMP
activity in RXFP4 transfected cells in a dose-dependent
manner. The activity of the peptide was slightly lower than
H3 relaxin (Table 1) but similar to that previously described.
[11]
Figure 4. A) Scheme for regioselective disulfide bond formation in human
INSL5. B) RP-HPLC profile of the purified synthetichuman INSL5 (eluant A:
0.1% aq. TFA; eluant B: 0.1% TFA in acetonitrile; gradient: 20–50% B over
30 min; Phenomenex C18 column, pore size 300  , particle size 5 mm,
4.6 250 mm).
Figure 5. CD spectra of human INSL5 and H3 relaxin in phosphate buffer
(10 mm) with NaCl (120 mm, pH 7.4).
Figure 6. 2D NMR spectrum of INSL5. NOESY spectrum of INSL5 (0.4 mg)
recorded at pH~4, 298 K, and 900 MHz. The parts of the “sequential walk”
that were used for resonance assignments are marked with connecting lines
for resonances in the B chain. The intraresidual Ha–HN cross-peaks are
labeled with residue numbers and single letter amino acid codes. The great
signal dispersion both in the NH dimension and the Ha dimension is
indicative of a well-structured peptide.
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We have described a highly efficient protocol through which
human INSL5 was successfully prepared for the first time in
good overall yield by a combination of SPPS and regioselective
disulfide bond formation. The syntheticINSL5 shows a typic al
insulin-like a-helical content along with b sheet and/random-
coiled structure according to CD spectroscopy, and, further-
more, has an overall similar structure to H3 relaxin—a related
member of the insulin superfamily—based on NMR spectros-
copy data. The peptide was able to inhibit cAMP activity in SK-
N-MC cells that expressed the human RXFP4 receptor with a
similar activity to H3 relaxin. In contrast, it had no activity on
the human RXFP3 receptor. Synthetic human INSL5, therefore,
demonstrates equivalent activity to the recombinant peptide
and will be a valuable probe for testing its biological function.
Experimental Section
General: Fmocamino ac id derivatives for peptide synthesis were
of the l configuration and were purchased from Auspep Pty. Ltd.
(Melbourne, Australia) or GL Biochem (Shanghai, China). RP-HPLC
columns were obtained from Phenomenex (Torrance, California,
USA). Solvents and chemicals were all peptide synthesis or analyti-
cal grade.
SPPS: The predicted primary structure of INSL5 consists of a
twenty one residue A chain and a twenty four residue B chain that
are linked by three disulfide bonds (Figure 1). Both regioselectively
S-protected A and B chains were separately synthesized by using
the continuous flow Fmoc solid-phase method
[45] with an automat-
icPerSeptive Biosystems Pioneer peptide synthesizer (Farmingham,
MA, USA), as previously reported.
[46] The solid support used for
both A and B chains was Fmoc-PAL-PEG-PS and a fourfold molar
excess of HBTU-activated l-Fmoc-amino acids were used through-
out. All amino acid side chains were protected by trifluoroacetic
acid (TFA)-labile protecting groups except for Cys8 (But) and Cys21
(Acm) in the A chain, and Cys19 (Acm) in the B chain. The scale of
assembly was 0.1 mmol for each of the two chains. The acylation
(coupling) reaction was carried out between 30 min to 1 h. Depro-
tection of the Fmoc group was with piperidine (20%)/DMF or DBU
(2%)/DMF. At the end of the synthesis, cleavage from the solid
supports and side-chain deprotection was achieved by 2 h treat-
ment with TFA (94%) in the presence of scavengers: anisole (3%),
3,6-dioxa-1,8-octanedithiol (DODT, 2%),
[47] and triisopropylsilane
(TIPS, 1%). The identities of the crude peptides were confirmed by
MALDI-TOF MS.
A chain intramolecular disulfide bond formation: The crude
[Cys8 (But), Cys21 (Acm)] A chain (190 mg, 81.55 mmol) was dis-
solved in GnHCl (6 m, 100 mL) with Gly·NaOH (0.1 m, pH 9) and di-
luted with water (500 mL); subsequently 2-pyridyl disulfide (DPDS;
57 mL of a 1 mm solution in MeOH) was added.
[48] The reaction
progress was monitored by analytical RP-HPLC. The retention time
of the intramolecularly oxidized A chain was earlier than that of
the reduced A chain (Figure 2). The reaction was completed in
30 min at room temperature. The large volume of solution was
loaded onto the preparative column through the pump’s C-line
and purified in several runs. The combined product was identified
by MALDI-TOF MS; m/z 2331.488 [M+H]
+, calcd 2330.59. The puri-
fied solution was freeze dried to give 60.0 mg of purified [Cys8
(But), Cys21 (Acm)] A chain (yield 31.6%).
A-chain conversion of Cys8 (But) to Cys8 (Pyr): The purified [Cys8
(But), Cys21 (Acm)] A chain (58.6 mg, 25.2 mmol) and 2-DPDS
(22.0 mg, 100.0 mmol) were dissolved in TFA/anisole (9:1, v/v;
1.63 mL). The solution was chilled on ice before TFMSA/TFA (1:4,
v/v; 1.63 mL) was added. The reaction was performed for 1 h at
08C, and the peptide was collected by diethyl ether precipitation,
centrifuged, and purified by preparative RP-HPLC. The freeze dried
purified product weighed 21.0 mg (8.81 mmol, 31.2%) and was
identified by MALDI-TOF MS; m/z 2384.15 [M+H]
+, calcd 2384.59.
Chain combination: The [Cys8 (Pyr), Cys21 (Acm)] A chain peptide
(20.0 mg, 8.4 mmol) was dissolved in GnHCl (6m), Gly·NaOH buffer
(0.1m, pH 9; 10 mL). The [Cys7 (S-thiol), Cys19 (Acm)] B chain
(25.0 mg, 8.6 mmol) was dissolved in deionized water (6 mL) and
was added slowly to the A chain solution. The reaction was moni-
tored by analytical RP-HPLC and the product was identified by
MALDI-TOF MS; m/z 5187.45 [M+H]
+, calcd 5187.57. The reaction
was complete within 1 h at room temperature under a nitrogen at-
mosphere. Neat TFA was added and the product was purified by
preparative RP-HPLC and freeze dried to give 15.50 mg (2.98 mmol,
34.7% relative to B chain) of [Cys21A (Acm)/Cys19B (Acm)]–A–B.
INSL5: The A–B peptide [Cys21A (Acm)/Cys19B (Acm)] (14.0 mg,
2.7 mmol) was dissolved in glacial acetic acid (8.5 mL) and HCl
(60 mm, 1.0 mL), and iodine/acetic acid (11.4 mL of a 20 mm solu-
tion) was then added to the solution. The reaction was monitored
by analytical HPLC. After 1 h the reaction was stopped by direct
addition of ice-cold diethyl ether. The final product was purified
Figure 7. The cAMP activity of human INSL5 compared to H3 relaxin in
RXFP3 and RXFP4 transfected cells. Data are meanSEM of triplicate
determinations from at least four independent experiments.
Table 1. Activity (pEC50
[a]) of INSL5 and H3 relaxin on RXFP3 and RXFP4.




H3 relaxin 9.370.18 (n=5) 9.430.16 (n=4)
[a] The pEC50 is defined as the negative logarithm of EC50—the concentra-
tion of agonist (INSL5) that produced 50% maximal response; [b] no ac-
tivity; [c] p<0.01 versus H3 relaxin.
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J. D. Wade et al.with preparative HPLC, and freeze dried to give 1.4 mg
(0.278 mmol, 10.3%). The peptide was identified by MALDI-TOF MS
as a single species; m/z 5043.721 [M+H]
+, calcd 5043.015; the
purity was examined by analytical RP-HPLC (Figure 4). The amino
acid composition and peptide content (38.8%) was determined by
amino acid analysis.
Circular dichroism spectroscopy: CD spectra were recorded by
using JASCO (J-185, Tokyo, Japan) at room temperature (208C)
with a 1 mm path length cell. The peptides were dissolved in phos-
phate buffer (10 mm) with NaCl (120 mm, pH 7.4) at a concentra-
tion of 0.1 mgmL
1.
NMR spectroscopy: For NMR spectroscopy a sample that con-
tained INSL5 (1 mg in 0.5 mL 90% H2O/10% D2O) was prepared.
The 2D homonuclear spectra, including TOCSY and NOESY, with a
mixing time of 150 ms spectra were recorded at pH~4 and 298 K
by using a Bruker Avance 900 MHz spectrometer and processed
with Topsin (Bruker).
cAMP activity assays: The syntheticINSL5 peptide was tested for
its ability to inhibit cAMP activity in SK-N-MC cells (human cauca-
ACHTUNGTRENNUNGsian neuroblastoma cells) that transiently expressed either RXFP3
or RXFP4. Human RXFP3 and RXFP4 in the mammalian expression
vector pcDNA3.1(+)zeo were obtained from the UMR cDNA Re-
source Center (http://www.cdna.org). The SK-N-MC cells were cul-
tured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium
(DMEM; Multicel) and HAMS-F12 (Multicel) supplemented with
fetal bovine serum (10%) and incubated in a humidified incubator
with 5% CO2 at 378C. Cells were seeded at 30000 cells per well in
96-well plates that were coated with poly-l-lysine (Sigma), and
were incubated, overnight, at 378C. After incubation they were
transfected with the receptor of interest together with a pCRE b-
galactosidase reporter plasmid
[49] and then incubated for a further
24 h. The cAMP activity of INSL5 in comparison to H3 relaxin was
then assessed in cells stimulated with forskolin (5 mm) as previously
described.
[50] Peptides were measured in triplicate within each
assay and each experiment was repeated at least four times. Data
were plotted by using GraphPad Prism 4 and statistical differences
in pEC50 values were determined with a Student t-test.
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